Routine varicella vaccination program and hospitalization for herpes zoster in Japan

2021 ◽  
pp. 1-6
Author(s):  
Yasutaka Kuniyoshi ◽  
Haruka Tokutake ◽  
Natsuki Takahashi ◽  
Azusa Kamura ◽  
Sumie Yasuda ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
Vaccination Program ◽  
Varicella Vaccination

Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program

Vaccine ◽  
2011 ◽  
Vol 29 (47) ◽  
pp. 8580-8584 ◽  
Author(s):  
Peter Tanuseputro ◽  
Brandon Zagorski ◽  
Kevin J. Chan ◽  
Jeffrey C. Kwong
Keyword(s):  
Herpes Zoster ◽  
Population Based ◽  
Vaccination Program ◽  
Varicella Vaccination ◽  
Publicly Funded

CDC suppression of deleterious data associated with the US universal varicella vaccination program: the effect of declining exogenous exposures on herpes zoster incidence rates (Preprint)

2019 ◽  
Author(s):  
Gary S. Goldman
Keyword(s):  
Herpes Zoster ◽  
Los Angeles ◽  
Vaccine Efficacy ◽  
Varicella Vaccine ◽  
Incidence Rates ◽  
Vaccination Program ◽  
Varicella Vaccination ◽  
The Us ◽  
Capture Recapture ◽  
Herpes Zoster Incidence

BACKGROUND A Research Analyst provides evidence that the Universal Varicella Vaccination Program dramatically altered the epidemiology of herpes zoster (HZ, or shingles) in the first decade following varicella vaccine licensure in March 1995, and describes how CDC misrepresented data to conceal the significance of exogenous (external) exposures in (1) augmenting varicella vaccine efficacy, and (2) helping to prevent or postpone reactivation of HZ. OBJECTIVE Provide data demonstrating the significant effect that the Universal Varicella Vaccination Program and concomitant decline in exogenous exposures had on augmenting varicella vaccine efficacy and on increasing herpes zoster incidence rates among children, adolescents, and adults with a history of varicella during the first decade following varicella vaccine licensure. METHODS The Varicella Active Surveillance Project (VASP) was one of three CDC-funded projects in the US whose mission was to monitor the effects of the varicella vaccine on the Antelope Valley (Los Angeles, California) population of 300,000 residents. In 1995, VASP started collecting baseline epidemiological data pertaining to varicella disease (excluding herpes zoster). Active surveilliance for HZ began in 2000. Since reporting sites consisted of schools and medical providers, two-source capture-recapture statistics were applied to determine reporting completeness of varicella and HZ cases among children and adolescents, and compute ascertainment-corrected incidence rates. RESULTS Deleterious trends in vaccine efficacy due to declines in exogenous exposures were masked by averaging varicella vaccine efficacy over several years instead of stratifying efficacy by year. High HZ incidence rates among children who previously had varicella were initially masked by reporting a crude HZ incidence rate that included varicella-vaccinated children. True rates in the population were approximately two-fold higher since capture-recapture estimated a reporting-completeness of 50%. VASP calculated a statistically significant increase of 56.1% in adult HZ case reports from 2000-2002. CONCLUSIONS CDC mainly published selective studies with misrepresented data to support universal varicella vaccination and aggressively blocked the Research Analyst’s attempt to publish deleterious trends or outcomes, prompting his resignation in protest against what he perceived was research fraud.

scholarly journals The Impact of the Varicella Vaccination Program on Herpes Zoster Epidemiology in the United States: A Review

2008 ◽  
Vol 197 (s2) ◽  
pp. S224-S227 ◽  
Author(s):  
Meredith A. Reynolds ◽  
Sandra S. Chaves ◽  
Rafael Harpaz ◽  
Adriana S. Lopez ◽  
Jane F. Seward
Keyword(s):  
United States ◽  
Herpes Zoster ◽  
The United States ◽  
Vaccination Program ◽  
Varicella Vaccination ◽  
The Impact

Effect of the Varicella Vaccination Implementation on the Development of Herpes Zoster in Children and Adolescents

2021 ◽  
Author(s):  
Inan Yuksel Esma ◽  
Kara Polat Asude ◽  
Gore Karaali Muge ◽  
Koku Aksu Ayse Esra ◽  
Gurel Mehmet Salih
Keyword(s):  
Herpes Zoster ◽  
Children And Adolescents ◽  
Varicella Vaccination

Association between Diabetes Mellitus and the Risk of Herpes Zoster: A Systematic Review and Meta-analysis

2021 ◽  
Author(s):  
Chun-Ta Huang ◽  
Chi-Yu Lee ◽  
Heng-You Sung ◽  
Shu-Jung Liu ◽  
Po-Chih Liang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Cardiovascular Disease ◽  
Herpes Zoster ◽  
Relative Risk ◽  
General Population ◽  
Confidence Interval ◽  
Varicella Vaccination ◽  
Cochrane Central Register ◽  
Case Control Studies ◽  
Increased Risk

Abstract Context Individuals with diabetes mellitus (DM) are susceptible to various infections. Objective We estimated the risk of herpes zoster (HZ) among individuals with DM compared to individuals in the general population. Data Sources We searched the PubMed, Embase, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trails, Cumulative Index to Nursing and Allied Health Literature and PerioPath databases from their inception to January 30, 2021 for studies on the risk of HZ in individuals with DM. Study Selection Two authors independently screened all articles identified. Data Extraction The same two authors independently extracted the data. Four case-control studies and 12 cohort studies were included. Data Synthesis Meta-analyses were performed using fixed and mixed-effects models. In the pooled analysis, individuals with DM had a higher risk of developing HZ (pooled relative risk: 1.38, 95% confidence interval: 1.21–1.57) than individuals in the general population. The results were consistent in subgroup analyses stratified by type of diabetes, age, and study design. In individuals with DM, cardiovascular disease had an additive effect on increasing the risk of HZ (pooled relative risk: 1.19, 95% confidence interval: 1.11–1.28). There was a linear dose-response association between age and the risk of HZ in individuals with DM. Conclusion Individuals with DM have an increased risk of HZ compared to the general population. Varicella vaccination should be provided to individuals with DM regardless of their age, prioritizing older adults and those with cardiovascular disease. Varicella vaccination policies for individuals with DM should be updated based on the evidence.

scholarly journals 2767. Variation in Incidence of Pediatric Herpes Zoster by First- and Second-Dose Varicella Vaccine Formulations

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S975-S976
Author(s):  
Sheila Weinmann ◽  
Stephanie Irving ◽  
Padma Koppolu ◽  
Allison Naleway ◽  
Edward Belongia ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
Varicella Vaccine ◽  
Vaccine Dose ◽  
Varicella Vaccination ◽  
Vaccine Formulation ◽  
Wild Type ◽  
Varicella Zoster ◽  
Dose Formulation ◽  
Using Data ◽  
Rate Ratios

Abstract Background Varicella (VAR) and measles-mumps-rubella (MMR) vaccines are recommended for children at ages 12–15 months and 4–6 years. These are administered as separate MMR and VAR vaccines (MMR+VAR) or as combined measles-mumps-rubella-varicella (MMRV) vaccine. Herpes zoster (HZ), caused by wild-type or vaccine-strain varicella-zoster virus, can occur in children after varicella vaccination. It is unknown whether HZ incidence after varicella vaccination varies by vaccine formulation or simultaneous receipt of MMR. Methods Using data from six integrated health systems, we examined HZ incidence among children who turned 12 months old during 2003–2008 and received varicella and MMR vaccines according to routine recommendations. All HZ cases ≥ 21 days after first varicella vaccination were identified using ICD-9 codes from inpatient, outpatient, emergency room encounters, and claims data, through 2014. HZ incidence was examined by vaccine formulation (MMR+VAR, MMRV, or VAR without same-day MMR) and doses received and compared using incidence rate ratios (IRR). Results Among 199,797 children, we identified 601 HZ cases. Crude HZ incidence after first-dose MMR+VAR (18.6 [95% CI 11.1–29.2] cases/100,000 person-years) was similar to the rate after first-dose MMRV (17.9 [95% CI 10.6–28.3] cases/100,000 person-years), but approximately double the rate among those with first-dose VAR without same-day MMR (7.5 [95% CI 3.1–15.0] cases/100,000 person-years); see Table 1. The IRR for HZ after first-dose MMR+VAR or MMRV, compared with VAR, was 2.5 (95% CI 1.4–4.4; P = 0.002). When examining any first or second dose formulation, crude HZ incidence was lower after the second varicella vaccine dose (13.9 cases/100,000 person-years), than in the period before the second dose (i.e., between first and second doses or after the first dose in children with only one dose; 21.8 cases/100,000 person-years, P < 0.0001). HZ incidence was also lower after two varicella vaccine doses in each of the three first-dose formulation groups. Conclusion HZ incidence among children varied by first-dose varicella vaccine formulation and number of varicella vaccine doses. Regardless of the first-dose varicella vaccine formulation, children who received two vaccine doses had lower HZ incidence after the second dose. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document